Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Ultragenyx receives U.K. approval to conduct phase I/II UX-003 trial

Aug. 19, 2013

Acasti Pharma reports data from phase II CaPre trial

Aug. 16, 2013

Eli Lilly discloses new MGAT2 inhibitors for hypertriglyceridemia

Aug. 16, 2013

Sanford-Burnham and Pfizer to identify targets for treatment of diabetes

Aug. 16, 2013

Japanese researchers patent novel agents for promoting osteogenesis

Aug. 16, 2013

Reliable insulin delivery seen with Adagio inhalable insulin in phase I/II trial

Aug. 16, 2013

Preclinical characterization of a GIP analogue for the treatment of diabetes

Aug. 16, 2013

Cystinosis Research Foundation issues six grants in the U.S. and Canada

Aug. 14, 2013

MatinasBioPharma receives financing for omega-3 candidate

Aug. 14, 2013

Avanir Pharmaceuticals and Merck enter co-promotion agreement for Januvia

Aug. 13, 2013

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...